LIFECORE BIOMEDICAL, INC. DE(LFCR)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,523 of 2,962 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
LFCR Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for LIFECORE BIOMEDICAL, INC. DE (LFCR), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores LFCR at 29.7/100 on a 32-signal composite quality model, placing it at rank #2,523 of 2,962 stocks — the bottom half of the AI-ranked universe. Areas of concern include profitability (12.9) and balance sheet strength (13.2), which score below median versus the broader universe. Shareholder dilution risk is elevated at 19.1/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), LIFECORE BIOMEDICAL, INC. DE reports quarterly revenue of $34.2M, net income of $-6.2M, free cash flow of $880.0K. Top institutional holders of LFCR by reported 13-F value include WYNNEFIELD CAPITAL, Legion Partners Asset Management, Greenhaven Road Investment Management, L.P., based on the most recent SEC filings. LFCR trades on the Nasdaq exchange and files with the SEC under CIK 1005286. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate LFCR daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for LIFECORE BIOMEDICAL, INC. DE directly from SEC EDGAR. LIFECORE BIOMEDICAL, INC. DE's 13F Pro composite quality score has ranged between 20 and 40 since 2024, currently 29.7 — an improving long-term trajectory across 53 quarterly and live scoring snapshots.
Revenue
Q2 2026
$34.2M
Net Income
Q2 2026
$-6.2M
Free Cash Flow
Q2 2026
$880.0K
ROIC
Q2 2026
8.4%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
Net Income
Operating Income
EPS (Diluted)
Total Assets
-5.8% YoYTotal Debt
+11.8% YoYOp. Cash Flow
Free Cash Flow
| Metric | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Revenue | — | $128.9M +0.5% | $128.3M +24.2% | $103.3M -44.4% | $185.8M +8.3% | $171.5M |
| Net Income | — | $-38.7M -422.3% | $12.0M +112.1% | $-99.6M +13.2% | $-114.7M -251.1% | $-32.7M |
| Operating Income | — | $-17.2M -95.0% | $-8.8M +59.4% | $-21.8M +62.8% | $-58.6M -43667.2% | $-134.0K |
| EPS (Diluted) | — | $-1.27 -484.8% | $0.33 +109.9% | $-3.32 +14.9% | $-3.90 -248.2% | $-1.12 |
| Total Assets | $225.5M -5.8% | $239.3M -5.8% | $254.0M +0.2% | $253.5M -8.7% | $277.8M -44.8% | $502.9M |
| Total Debt | $149.7M +11.8% | $133.9M +6.6% | $125.6M +47.1% | $85.4M -56.5% | $196.4M +19.1% | $164.9M |
| Operating Cash Flow | — | $-206.0K -180.2% | $257.0K +101.5% | $-17.4M +28.5% | $-24.4M -262.5% | $15.0M |
| Free Cash Flow | — | $-13.6M +24.9% | $-18.1M | — | $-50.6M -1092.0% | $-4.2M |
Get alerted when LFCR's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for LIFECORE BIOMEDICAL, INC. DE including:
Top Institutional Holders of LFCR
WYNNEFIELD CAPITAL INC
$24.7M4,703,216 shLegion Partners Asset Management, LLC
$23.4M4,461,823 shGreenhaven Road Investment Management, L.P.
$16.8M3,190,769 sh325 CAPITAL LLC
$15.2M2,895,881 shBlackRock, Inc.
$10.6M2,013,093 shVANGUARD CAPITAL MANAGEMENT LLC
$6.8M1,288,621 shGEODE CAPITAL MANAGEMENT, LLC
$4.5M855,500 shMORGAN STANLEY
$4.0M769,360 shSTATE STREET CORP
$3.5M668,031 shQuinn Opportunity Partners LLC
$2.4M453,495 sh
| Fund | Value | Shares |
|---|---|---|
| WYNNEFIELD CAPITAL INC | $24.7M | 4,703,216 |
| Legion Partners Asset Management, LLC | $23.4M | 4,461,823 |
| Greenhaven Road Investment Management, L.P. | $16.8M | 3,190,769 |
| 325 CAPITAL LLC | $15.2M | 2,895,881 |
| BlackRock, Inc. | $10.6M | 2,013,093 |
| VANGUARD CAPITAL MANAGEMENT LLC | $6.8M | 1,288,621 |
| GEODE CAPITAL MANAGEMENT, LLC | $4.5M | 855,500 |
| MORGAN STANLEY | $4.0M | 769,360 |
| STATE STREET CORP | $3.5M | 668,031 |
| Quinn Opportunity Partners LLC | $2.4M | 453,495 |
Companies Similar to LFCR
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
REGENXBIO Inc.
Alpha Teknova, Inc.
Sanara MedTech Inc.
CASTLE BIOSCIENCES INC
ARDELYX, INC.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put LFCR on your watchlist
Track score changes the day LIFECORE BIOMEDICAL, INC. DE files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is LFCR a good stock to buy?
13F Pro's AI-powered analysis of LIFECORE BIOMEDICAL, INC. DE (LFCR) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for LFCR are available on the LFCR stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. LFCR is classified as a small company.
Which hedge funds own LFCR?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling LFCR. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of LIFECORE BIOMEDICAL, INC. DE's investment landscape.